Septic shock is characterized by a dysregulated response to infection, hypotension and activation of the coagulation system. Markers of coagulation activation are commonly used to diagnose and monitor ensuing coagulopathies. In this study, we sought to determine levels of circulating thrombin in patients with septic shock. To characterize levels of circulating, active thrombin in patients with septic shock. 48 patients with septic shock were included in this prospective, observational study. Blood samples were obtained on admission, day 1, day 3 and day 6. Levels of active thrombin were measured using a standardized, clinically applicable oligonucleotide (aptamer)-based enzyme-capture assay (OECA). Thrombin levels were correlated with established indirect thrombin parameters, conventional coagulation tests, laboratory parameters, patient characteristics and outcome. Elevated levels of thrombin were detected in 27 patients (56.3%) during the course of the study. Thrombin levels were positively correlated with thrombin-antithrombin complexes (r = 0.30, p < 0.05) and negatively associated with FVII levels (r = − 0.28, p < 0.05). Thrombin levels on admission did not predict 30-day mortality (OR 0.82, 95% CI 0.23–2.92, p = 0.77). Circulating levels of active thrombin can be measured in a subset of patients with septic shock. Although thrombin levels are correlated with established markers of coagulation, they do not provide additional prognostic information.
This is a preview of subscription content, log in to check access.
The authors thank the Klaus Tschira Charitable Foundation for its kind support. The authors further thank Simone Gasper for expert technical assistance.
TB, SB and DL designed the study and drafted the manuscript. JM and KS analysed and interpreted the data. IA was a major contributor in writing the manuscript. BP, DL, JM and MB revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript
This study was funded by the Klaus Tschira Charitable Foundation (Grant No. 00.271.2015).
Compliance with ethical standards
Conflict of interest
Martin Borggrefe declares financial relations, including speaker honoraria and research grants, with Boston Scientific, Medtronic, Impulse Dynamics, St. Jude Medical, CVRx, Biotronic, Pfizer, Bayer and Böhringer-Ingelheim. All other authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (University of Heidelberg, Germany; reference number 2015-526N-MA) and with the 1964 Helsinki declaration and its later amendments.
Informed consent was obtained from all individual participants included in the study.
Lelubre C, Vincent JL (2018) Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol 14(7):417–427CrossRefGoogle Scholar
Rhee C, Dantes R, Epstein L et al (2017) Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 318(13):1241–1249CrossRefGoogle Scholar
de Grooth HJ, Postema J, Loer SA, Parienti JJ, Oudemans-van Straaten HM, Girbes AR (2018) Unexplained mortality differences between septic shock trials: a systematic analysis of population characteristics and control-group mortality rates. Intensiv Care Med 44(3):311–322CrossRefGoogle Scholar
Lyons PG, Micek ST, Hampton N, Kollef MH (2018) Sepsis-associated coagulopathy severity predicts hospital mortality. Crit Care Med 46(5):736–742CrossRefGoogle Scholar
Saracco P, Vitale P, Scolfaro C, Pollio B, Pagliarino M, Timeus F (2011) The coagulopathy in sepsis: significance and implications for treatment. Pediatr Rep. 3(4):e30CrossRefGoogle Scholar
Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J (1996) Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 88(3):881–886CrossRefGoogle Scholar
Becher T, Muller J, Akin I et al (2018) The evolution of activated protein C plasma levels in septic shock and its association with mortality: a prospective observational study. J Crit Care 47:41–48CrossRefGoogle Scholar
Ruhl H, Muller J, Harbrecht U et al (2012) Thrombin inhibition profiles in healthy individuals and thrombophilic patients. Thromb Haemost 107(5):848–853CrossRefGoogle Scholar
Muller J, Becher T, Braunstein J et al (2011) Profiling of active thrombin in human blood by supramolecular complexes. Angew Chem Int Ed Engl 50(27):6075–6078CrossRefGoogle Scholar
Ruhl H, Winterhagen FI, Berens C, Muller J, Oldenburg J, Potzsch B (2018) In vivo thrombin generation and subsequent APC formation are increased in factor V Leiden carriers. Blood 131(13):1489–1492CrossRefGoogle Scholar
Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41(2):580–637CrossRefGoogle Scholar
Muller J, Becher T, Mayer G, Potzsch B (2016) Aptamer-based enzyme capture assay for measurement of plasma thrombin levels. Methods Mol Biol 1380:179–189CrossRefGoogle Scholar
Muller J, Friedrich M, Becher T et al (2012) Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide-based enzyme capture assay. J Thromb Haemost 10(3):390–398CrossRefGoogle Scholar
Konigsbrugge O, Koder S, Riedl J, Panzer S, Pabinger I, Ay C (2017) A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability. Clin Exp Med 17(2):251–256CrossRefGoogle Scholar
Koyama K, Madoiwa S, Nunomiya S et al (2014) Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Crit Care 18(1):R13CrossRefGoogle Scholar
Simmons J, Pittet JF (2015) The coagulopathy of acute sepsis. Curr Opin Anaesthesiol 28(2):227–236CrossRefGoogle Scholar
Takahashi H, Wada K, Niwano H, Shibata A (1992) Comparison of prothrombin fragment 1 + 2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation. Blood Coagul Fibrinolysis 3(6):813–818CrossRefGoogle Scholar
Franco RF, de Jonge E, Dekkers PE et al (2000) The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 96(2):554–559CrossRefGoogle Scholar
Pawlinski R, Wang JG, Owens AP 3rd et al (2010) Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood 116(5):806–814CrossRefGoogle Scholar
Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu O (1998) Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 26(12):2005–2009CrossRefGoogle Scholar
Kinasewitz GT, Yan SB, Basson B et al (2004) Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 8(2):R82–R90CrossRefGoogle Scholar